Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Verekitug - Upstream Biosciences

Next Previous
Search
Drug Profile

Verekitug - Upstream Biosciences

Alternative Names: ASP-7266; UPB-101

Latest Information Update: 27 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astellas Pharma
  • Developer Astellas Pharma; Upstream Biosciences
  • Class Anti-inflammatories; Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action CRLF2 protein antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma; Nasal polyps; Rhinosinusitis

Most Recent Events

  • 12 Mar 2025 Upstream Biosciences completes enrolment in its phase II trial in Nasal polyps (In adults, In the elderly) in USA, Czech Republic, Germany, Poland, Spain (SC) (NCT06164704)
  • 10 Oct 2024 Upstream Biosciences plans a phase-II trial for Chronic obstructive pulmonary disease in second half of 2025 (SC), (Upstream Biosciences website, October 2024)
  • 09 Sep 2024 Pharmacokinetics and pharmacodynamics data from a phase Ib trial in Asthma released by Upstream Biosciences

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top